Tag Archives: Humira

AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle

AbbVie’s strength has long been tied to the performance of megablockbuster Humira, which is facing an existential threat as U.S. copycats creep closer. Despite a “more aggressive” than expected biosimilar challenge abroad, AbbVie believes its defense strategy—and lessons learned—will help it weather the storm. In an earnings call with analysts Friday, AbbVie CEO Rick Gonzalez touted the drugmaker’s… Read More »

AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023

AbbVie is on a hot streak striking patent deals to protect its top drug, Humira. Even as Boehringer Ingelheim has opted to fight the company’s patent claims in court, Pfizer has decided it’s in its own best interest to settle on a late 2023 biosimilar launch date. Under a licensing agreement with AbbVie, Pfizer can… Read More »